Therapeutic MK2 inhibition blocks pathological vascular smooth muscle cell phenotype switch
Open Access
- 8 October 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (19)
Abstract
Vascular procedures, such as stenting, angioplasty, and bypass grafting, often fail due to intimal hyperplasia (IH), wherein contractile vascular smooth muscle cells (VSMCs) dedifferentiate to synthetic VSMCs, which are highly proliferative, migratory, and fibrotic. Previous studies suggest MAPK-activated protein kinase 2 (MK2) inhibition may limit VSMC proliferation and IH, although the molecular mechanism underlying the observation remains unclear. We demonstrated here that MK2 inhibition blocked the molecular program of contractile to synthetic dedifferentiation and mitigated IH development. Molecular markers of the VSMC contractile phenotype were sustained over time in culture in rat primary VSMCs treated with potent, long-lasting MK2 inhibitory peptide nanopolyplexes (MK2i-NPs), a result supported in human saphenous vein specimens cultured ex vivo. RNA-Seq of MK2i-NP–treated primary human VSMCs revealed programmatic switching toward a contractile VSMC gene expression profile, increasing expression of antiinflammatory and contractile-associated genes while lowering expression of proinflammatory, promigratory, and synthetic phenotype–associated genes. Finally, these results were confirmed using an in vivo rabbit vein graft model where brief, intraoperative treatment with MK2i-NPs decreased IH and synthetic phenotype markers while preserving contractile proteins. These results support further development of MK2i-NPs as a therapy for blocking VSMC phenotype switch and IH associated with cardiovascular procedures.Keywords
Funding Information
- National Institute of Health (R01HL122347,T32GM007347)
- National Science Foundation (STTR 1622828)
This publication has 62 references indexed in Scilit:
- Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivoVascular Pharmacology, 2012
- A novel cell permeant peptide inhibitor of MAPKAP kinase II inhibits intimal hyperplasia in a human saphenous vein organ culture modelJournal of Vascular Surgery, 2010
- Molecular Regulation of Contractile Smooth Muscle Cell Phenotype: Implications for Vascular Tissue EngineeringTissue Engineering Part B: Reviews, 2010
- The Stent-Eluting Drugs Sirolimus and Paclitaxel Suppress Healing of the Endothelium by Induction of AutophagyThe American Journal of Pathology, 2009
- Design of a bioactive cell‐penetrating peptide: when a transduction domain does more than transduceJournal of Peptide Science, 2009
- TGF-β through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- miR-145 and miR-143 regulate smooth muscle cell fate and plasticityNature, 2009
- Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscleAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Development of a novel endosomolytic diblock copolymer for siRNA deliveryJournal of Controlled Release, 2009
- Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasiaProceedings of the National Academy of Sciences, 2007